Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Bristol Myers Squibb's experimental cell therapy, arlo-cel, hit its primary endpoint in a mid-stage trial for multiple myeloma. The therapy showed significant improvement in patient response rates and helped more patients achieve a complete response — meaning no detectable cancer remained. It's an encouraging early signal for a notoriously difficult-to-treat blood cancer.
Bristol Myers Squibb's experimental cell therapy, arlocabtagene autoleucel (arlo-cel), cleared a key hurdle in its mid-stage clinical trial, meeting its primary endpoint in patients with a hard-to-treat form of multiple myeloma — a blood cancer that affects plasma cells in the bone marrow.
The trial demonstrated a significant improvement in the overall response rate among treated patients. A key secondary goal was also met: more patients achieved a complete response, meaning no signs of cancer were detectable after treatment — a meaningful bar in oncology trials.
Key Takeaways:
Why it matters: Multiple myeloma remains largely incurable, and patients who relapse after standard treatments have few effective options. A cell therapy that drives high response and complete remission rates could represent a meaningful step forward for this patient population, and sets the stage for larger, confirmatory trials.
